Novo Nordisk A/S (NVO) to Release Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) will announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.91 per share for the quarter. Novo Nordisk A/S has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. On average, analysts expect Novo Nordisk A/S to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $109.72 on Tuesday. The firm’s fifty day simple moving average is $123.74 and its 200 day simple moving average is $130.85. The stock has a market cap of $492.37 billion, a P/E ratio of 37.58, a price-to-earnings-growth ratio of 1.46 and a beta of 0.43. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.